Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Huntington’s disease
Biotech
Bayer drops Huntington's gene therapy
Bayer is the latest in a long line of drug developers to give up on Huntington’s disease after the pharma giant canned a phase 1 gene therapy.
James Waldron
Nov 12, 2024 10:09am
Takeda axes Huntington’s pact, freeing Wave to pursue partners
Oct 16, 2024 8:07am
Novartis, Voyager launch $100M gene therapy mission
Jan 2, 2024 8:31am
uniQure Huntington's gene therapy data 'on the favorable side'
Dec 19, 2023 11:28am
Scientists look to survival secrets of plants for Huntington's
Oct 3, 2023 10:51am
Roche pays Ionis $60M to license Alzheimer's, Huntington's drugs
Sep 27, 2023 8:56am
